Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Virtual Advocacy Inspires the Next Generation of Rheumatology Professionals

Kimberly Retzlaff  |  August 5, 2021

Brenda Lee Frie, EdD, OTR/L, CHT, uses her experiences in professional advocacy to inspire her students to get involved and make a difference from the earliest stages of their careers.

Efficacy of Tocilizumab Monotherapy After Ultra-Short Glucocorticoid Administration in GCA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a small study, patients with GCA maintained remission after receiving three days of treatment with methylprednisolone followed by tocilizumab.

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).

AbbVie, Lilly Face New Delays in FDA Approval for Expanded Use of Janus Kinase Inhibitors

Natasha Yetman  |  July 26, 2021

(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus…

CDC Advisers Consider Boosters for Immune-Compromised Americans

Julie Steenhuysen  |  July 26, 2021

CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…

Will an App to Monitor Patient Outcomes Improve RA Disease Activity?

Arthritis & Rheumatology  |  July 26, 2021

Lee et al. examined the use of a smartphone application to monitor longitudinal electronic patient-reported outcomes on satisfaction and disease activity in patients with RA.

Learn to Share Your Voice at Advocacy 101

From the College  |  July 20, 2021

Applications are now open for the ACR’s Advocacy 101 program, held in conjunction with Advocates for Arthritis. Amanda Schnell, MD, describes how ACR/ARP members can learn to be successful advocates for rheumatology.

2022 Physician Fee Schedule Proposed Rule Released

From the College  |  July 20, 2021

In the proposed rule released July 13, the ACR is encouraged by the continued implementation of evaluation and management reimbursement adjustments to better reflect the work and expertise needed to treat complex patient populations, the extension of many telehealth flexibilities and the inclusion of the ACR’s proposed MACRA MIPS Value Pathway for rheumatology.

Executive Order Targets Prescription Drugs & Health Insurance to Promote Competition

Natasha Yetman  |  July 19, 2021

On July 9, U.S. President Joe Biden issued an Executive Order designed to promote competition in the U.S. economy. The order includes 72 initiatives related to various aspects of the economy, including prescription drugs and health insurance.1 For prescription drugs, Americans pay more than 2.5 times as much for the same prescription drugs as patients…

Steven Echard Shares ACR Collaborative Plans at Florida Society Meeting

Vanessa Caceres  |  July 19, 2021

At the recent Florida Society of Rheumatology meeting, ACR executive vice president Steven Echard, IOM, CAE, emphasized the role of collaborations with state organizations in the ACR’s plans to modernize and expand its activities and offerings.

  • « Previous Page
  • 1
  • …
  • 137
  • 138
  • 139
  • 140
  • 141
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences